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In this issue of Cancer Biology & Therapy, Kisslinger et al. demon-
strated for the first time that Proline-rich tyrosine kinase (Pyk2) and 
cAMP interact in regulating prostate cell functions and in “keeping” 
prostate identity.1 In EPN cells, a line of non-transfomed epithelial 
cells derived from human normal tissue, cAMP potently inhibits 
growth (~90% after eight days) and preserves prostate differentiation 
through Pyk2 phosphorylation. The antiproliferative effect medi-
ated by Pyk2 activation seems to be a consequence of abolishing 
AKT1 phosphorylation. While in EPN-PKM3 cells, an EPN clone 
bearing a Pyk2 kinase-negative mutant, cAMP incubation induces 
a moderate inhibition in cell proliferation (-35%), the remaining 
AKT1 was still activated for up to 72 hours and shifted prostate cells 
towards a neuroendocrine phenotype. In fact, analysis of the expres-
sion of the HOX gene network revealed that Pyk2 function alone did 
not affect HOX gene expression, but cAMP stimulation induced a 
modulation of HOX D and C genes, which are involved in neuroen-
docrine differentiation.
Pyk2 is a non-receptor tyrosine kinase of the focal adhesion kinase 
(FAK) family, involved in several cellular functions such as adhesion, 
motility, anchorage independence, cell proliferation, apoptosis and 
the G1 to S phase transition of the cell cycle.
2,3 Pyk2 seems to have 
a main role in the tumorigenesis, differentiation and invasiveness 
of prostate cancer. In fact, Pyk2 is functionally expressed in both 
normal and neoplastic prostate tissue. The expression of this tyrosine 
kinase is inversely correlated to the degree of prostate malignancy. 
Pyk2 progressively decreases as the grade of the adenocarcinoma 
increases until disappearing in anaplastic, undifferentiated cancer.4,5 
This suggests that in the prostate Pyk2 may play the role of an onco-
suppressor gene, while its expression or lack of expression could reflect 
the state of differentiation of the tumor. In addition, a decrease in 
the expression of Pyk2 resulted in a MAP kinase-dependent decrease 
in the proliferation of prostate cells, while the loss of Pyk2 kinase 
activity in EPN-PKM3 cells correlated with increased cell motility 
and migration.6,7 However, most of these data were obtained in 
non-transformed epithelial cells, while several studies on prostate 
cancer cells suggest an involvement of Pyk2 activation in invasion 
processes.8,9 Therefore, an inverse role of Pyk2 in cancer cells cannot 
be excluded; where signal transduction pathways are deregulated and 
the normal interactions and feed-back loops between proliferative 
and growth suppressing pathways are lacking due to multiple muta-
tions acting at several levels.
In most cases Pyk2 is involved in integrin-mediated signal trans-
duction. Pyk2 is activated after integrin clustering in response to 
various extracellular matrix components, such as fibronectin and 
by a number of growth factor receptors, including ErbB tyrosine 
kinases. After activation, Pyk2 undergoes multiple phosphorylations 
and engages in protein-protein interactions with a variety of proteins 
including cytoskeletal proteins, such as paxillin; tyrosine kinases, 
such as Src and C-terminal src-kinase; serine/threonine kinases, such 
as integrin-linked kinase and p21-activated kinase; and modulators 
of small GTPases of the Rho family. These multiple interactions have 
been established as critical regulators of early cell invasion signalling, 
promoting cancer cell migration and the initiation of metastasis 
formation.3 In EPN-PKM3 prostate cells the loss of Pyk2 activity 
upregulates expression of the α5-integrin subunit, which mediates 
adhesion to fibronectin.7 Expression of α5-integrin correlates with 
the resistance of prostate cancer cells to undergo apoptosis.10,11 In the 
human prostate cancer cell line PC-3, upregulation of α5-integrin is 
associated with increased adhesion to the extracellular matrix protein 
fibronectin, thereby facilitating colonization of the bone matrix 
where these cells preferentially metastasize.12,13 Therefore Pyk2 
plays a central role in the mechanisms that regulate cell-cell and 
cell-substrate interactions. The lack of Pyk2 kinase activity induces 
normal prostate cells to acquire a malignant, invasive, highly prolif-
erating and migrating phenotype.
Cyr61, a member of growth factor-inducible immediate-early 
genes belonging to the CCN family, plays an important role in 
cell proliferation, adhesion and differentiation of prostatic stromal 
and epithelial cells and in the processes of tumorigenesis and inva-
siveness of prostate cancer.14-16 These biological properties are 
mainly modulated by interactions with cell surface integrins because 
Cyr61 functions as a bridge between cell membrane integrins and 
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Role of Pyk2 and Cyr61 in prostate cancer
extracellular matrix components (i.e., fibronectin). In PCa, a pros-
tate cancer cell line, Cyr61 regulated the level of activated Rac1 
as well as its downstream targets, including phosphorylated JNK, 
E-cadherin and p27(kip1), which are key molecules involved in cell 
growth, migration and invasion.16 In other tumor models it has been 
shown that CYR61 cooperates with integrins to promote metastasis, 
peritoneal disseminations, tumour proliferation and resistance to 
apoptosis.17-20
It is interesting to observe that as for Pyk2, Cyr61 is regulated 
through the cAMP signal transduction pathway. In fact, cAMP 
responsive element-binding protein (CREB) positively regulates the 
expression of Cyr61 in response to hypoxia in vitro and activates 
Cyr61 gene expression in correlation with hypoxic regions in tumors 
in vivo.21 Therefore, cAMP increases the expression of both Cyr61 
and Pyk2. It will be important to check the interaction between Pyk2 
and Cyr61 in these experimental models and their correlations with 
the cAMP-dependent pathway, cell proliferation, neuroendocrine 
differentiation and tumor invasiveness (Fig. 1). The interaction 
between components of the machinery involved in the control of 
cell adhesion and motility could have a pivotal role in the regulation 
of both proliferation and cAMP-mediated commitment to neuro-
endocrine differentiation. In this view, a series of potential proteins 
for stromal signaling and the bladder or prostate differentiation 
program including cathepsin L, follistatin-related protein, neuroen-
docrine convertase, tumor necrosis factor receptor and others was 
recently identified. The prostate stromal/epithelial signaling may be 
accomplished through activation of the interaction between extracel-
lular matrix molecules and receptors, complement and coagulation 
cascades, focal adhesion and cell adhesion pathways (including 
Pyk2).22 In conclusion, the data by Kisslinker et al.1 may provide a 
new class of targets that can be used for the design of new strategies 
in prostate cancer treatment.
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Figure 1. Hypothesis of the interaction between Pyk2 and Cyr61 under the 
control of the cAMP-dependent pathway in the modulation of cell proliferation, 
neuroendocrine differentiation and tumor invasiveness in prostate cancer.
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